Back to Research Home
HALOHalozyme Therapeutics Inc
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · Large
$125.63+0.88%
As of 23 Oct 2026Mkt cap $12.4B
Stage 13
WAIT
Fundamentals
49.4/75
Technical
5.3/15
Independent
54.7/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- +9.0%
- 3M
- +54.2%
- 6M
- +92.2%
- 1Y
- +91.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 37.1xHist median 16.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 19.3x
- FCF yield
- 5.2%
Quality
- ROIC
- 16.5%
- Operating margin
- 40.7%
- FCF margin
- 46.2%
- Current ratio
- 4.7x
Growth
- Revenue growth
- +37.6%Latest FY YoY
- Revenue CAGR
- +33.2%
- EPS CAGR
- −1.7%
- FCF CAGR
- +21.3%
Capital
- Share-count trend
- −3.9%3Y annualised
- Net debt
- $2.0B3.1x OCF
Annual trend
- CAGR 2021–2025
- +33.2%
- Latest · 2025
- $1B
- YoY
- +37.6%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded